Nutanix Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? Nutanix Inc trades at $69.38 (market cap $18.90B), while Vir Biotechnology Inc. Common Stock trades at $10.49 (market cap $1.76B). The key difference: Nutanix Inc is far larger — about 10.7× Vir Biotechnology Inc. Common Stock's market cap, and Nutanix Inc is more actively traded (3,504,387 versus 2,764,948). Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| NTNX | VIR | |
|---|---|---|
Market Cap | $18.90B | $1.76B |
Volume | 3,504,387 | 2,764,948 |
Sector | Technology | Health |
52-Week High | $74.63 | $11.78 |
52-Week Low | $34.41 | $5.12 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $18.06B | $1.32B |
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $72.88, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and recent earnings beats. The company reported robust Q4 2026 results exceeding expectations, with revenue growth to $2.9B and net profit margin expanding to 52.8%. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms.
Outlook remains positive with 62.5% analyst buy ratings and $76.11 consensus price target, though elevated P/S ratio and negative ROE warrant monitoring. Key risks include supply chain pressures and competitive threats in cloud infrastructure, while AI growth initiatives present long-term opportunity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →